Fentermin etkileşimleri

MSS uyarıcısı sınıfından Fentermin (Adipex-P, Lomaira) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 196 belgelenmiş etkileşim var: 45 majör, 113 orta, 38 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 0 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (45)

  • AdrenalinsempatomimetikMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • AmfetaminMSS uyarıcısıMajör

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [ see Adverse Reactions (6) ] . (Amfetamin etiketi, Kontrendikasyonlar)

  • Amfetamin ve dekstroamfetaminMSS uyarıcısıMajör

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6.2 )] . taking monoamine oxidase inhibitors (MAOIs), or within 14 days of stopping MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because of an increased risk of hypertensive… (Amfetamin ve dekstroamfetamin etiketi, Kontrendikasyonlar)

  • Arformoterolbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • BenzfetaminMSS uyarıcısıMajör

    Benzphetamine Hydrochloride Tablets should not be used concomitantly with other CNS stimulants. (Benzfetamin etiketi, Kontrendikasyonlar)

  • …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • Budesonid ve formoterolkortikosteroidMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • DekstroamfetaminMSS uyarıcısıMajör

    CONTRAINDICATIONS Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy to the sympathomimetic amines, glaucoma. (Dekstroamfetamin etiketi, Kontrendikasyonlar)

  • DronabinolkannabinoidMajör

    Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (Dronabinol etiketi, Uyarılar ve önlemler)

  • FendimetrazinMSS uyarıcısıMajör

    …hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy (see PRECAUTIONS, Pregnancy ) • Nursing • Use in combination with other anorectic agents or CNS stimulants • Known hypersensitivity or idiosyncratic reactions to sympathomimetics (Fendimetrazin etiketi, Kontrendikasyonlar)

  • FenelzinMAO inhibitörüMajör

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fentermin etiketi, Kontrendikasyonlar)

  • FenilefrindekonjestanMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • Fentermin ve topiramatMSS uyarıcısıMajör

    …(8.1) ] With glaucoma [see Warnings and Precautions (5.3) ] With hyperthyroidism Taking or within 14 days of stopping a monoamine oxidase inhibitors [see Drug Interactions (7) ] With known hypersensitivity to phentermine, topiramate or any of the excipients in phentermine and topiramate extended-release capsules, or idiosyncrasy to the sympathomimetic amines. (Fentermin ve topiramat etiketi, Kontrendikasyonlar)

  • Flutikazon ve salmeterolkortikosteroidMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • Formoterolbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • İmipramintrisiklik antidepresanMajör

    Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines. (İmipramin etiketi, İlaç etkileşimleri)

  • İpratropium ve salbutamolantikolinerjikMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • İzoniazidantibiyotikMajör

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fentermin etiketi, Kontrendikasyonlar)

  • İzoprenalinbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • Kloroprokainlokal anestezikMajör

    Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (Kloroprokain etiketi, Uyarılar)

  • Kokainlokal anestezikMajör

    WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (Kokain etiketi, Kutulu uyarı)

  • Levosalbutamolbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • Levotiroksin ve liyotironintiroid hormonuMajör

    Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Levotiroksin ve liyotironin etiketi, Kutulu uyarı)

  • LinezolidantibiyotikMajör

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fentermin etiketi, Kontrendikasyonlar)

  • Liyotironintiroid hormonuMajör

    • Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (Liyotironin etiketi, Kutulu uyarı)

  • Mepivakainlokal anestezikMajör

    Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (Mepivakain etiketi, Uyarılar)

  • MetamfetaminMSS uyarıcısıMajör

    Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Metamfetamin etiketi, Kontrendikasyonlar)

  • Metilen mavisiMAO inhibitörüMajör

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fentermin etiketi, Kontrendikasyonlar)

  • Mirabegronbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • OksimetazolindekonjestanMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • PimozidantipsikotikMajör

    Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have been withdrawn from these drugs to determine whether or not the drugs, rather than Tourette’s Disorder, are responsible for the tics. (Pimozid etiketi, Kontrendikasyonlar)

  • PrometazinantihistaminikMajör

    Epinephrine Because of the potential for Promethazine to reverse epinephrine's vasopressor effect, epinephrine should NOT be used to treat hypotension associated with Promethazine Syrup overdose. (Prometazin etiketi, İlaç etkileşimleri)

  • Prometazin ve dekstrometorfanantihistaminikMajör

    Epinephrine – Because of the potential for promethazine to reverse epinephrine’s vasopressor effect, epinephrine should NOT be used to treat hypotension associated with Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution overdose. (Prometazin ve dekstrometorfan etiketi, İlaç etkileşimleri)

  • ProtaminMajör

    Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine. (Protamin etiketi, Kutulu uyarı)

  • PsödoefedrindekonjestanMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • RasajilinMAO inhibitörüMajör

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fentermin etiketi, Kontrendikasyonlar)

  • Salbutamolbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • Salmeterolbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • SelejilinMAO inhibitörüMajör

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fentermin etiketi, Kontrendikasyonlar)

  • Sodyum oksibatMSS depresanıMajör

    Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials ( 14 )]. (Sodyum oksibat etiketi, Kutulu uyarı)

  • Terbutalinbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • Tizanidinkas gevşeticiMajör

    Hypotension: monitor for signs and symptoms of hypotension, in particular in patients receiving concurrent antihypertensives; Zanaflex should not be used with other α 2 -adrenergic agonists ( 5.1 , 7.7 ) (Tizanidin etiketi, Uyarılar ve önlemler)

  • TranilsiprominMAO inhibitörüMajör

    …cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) • During or within 14 days following the administration of monoamine oxidase inhibitors • Hyperthyroidism • Glaucoma • Agitated states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific… (Fentermin etiketi, Kontrendikasyonlar)

  • Umeklidinyum ve vilanterolantikolinerjikMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

  • Vibegronbeta adrenerjik agonistMajör

    …states • History of drug abuse • Pregnancy [ see Use in Specific Populations () ] • Nursing [ see Use in Specific Populations ( 8.3 ) ] • Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines • History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) () • During or within… (Fentermin etiketi, Kontrendikasyonlar)

Orta düzey etkileşimler (113)

  • AkarbozantidiyabetikOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • AklidinyumantikolinerjikOrta

    Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Aklidinyum etiketi, İlaç etkileşimleri)

  • AlkolAlkolOrta

    • Concomitant alcohol use may result in an adverse drug reaction. (Fentermin etiketi, Uyarılar ve önlemler)

  • AlogliptinDPP-4 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Alogliptin ve metforminDPP-4 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • AlprazolambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Alprazolam etiketi, Uyarılar ve önlemler)

  • AmiodaronantiaritmikOrta

    • Hypotension: Slow the infusion; as needed, add vasopressor drugs, positive inotropic agents, and volume expansion. (Amiodaron etiketi, Uyarılar ve önlemler)

  • Amitriptilintrisiklik antidepresanOrta

    When amitriptyline is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required. (Amitriptilin etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıOrta

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Asetazolamidkarbonik anhidraz inhibitörüOrta

    Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Asetazolamid etiketi, İlaç etkileşimleri)

  • BeksagliflozinSGLT2 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Brimonidin ve timololalfa adrenerjik agonistOrta

    If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Brimonidin ve timolol etiketi, Uyarılar ve önlemler)

  • BupropionantidepresanOrta

    …medications that lower the seizure threshold (e.g., other bupropion products, antipsychotics, tricyclic antidepressants, theophylline, and systemic corticosteroids), metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia), or use of illicit drugs (e.g., cocaine) or abuse or misuse of prescription drugs such as CNS stimulants. (Bupropion etiketi, Uyarılar ve önlemler)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • DapagliflozinSGLT2 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Dapagliflozin ve metforminSGLT2 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • DeksmetilfenidatMSS uyarıcısıOrta

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Desipramintrisiklik antidepresanOrta

    Close supervision and careful adjustment of dosage are required when this drug is given concomitantly with anticholinergic or sympathomimetic drugs. (Desipramin etiketi, İlaç etkileşimleri)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Desvenlafaksin etiketi, Uyarılar ve önlemler)

  • DiazepambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Diazepam etiketi, Uyarılar)

  • DietilpropionMSS uyarıcısıOrta

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Digoksindijital glikozidiOrta

    Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (Digoksin etiketi, İlaç etkileşimleri)

  • DisikloverinantikolinerjikOrta

    …drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Disikloverin etiketi, İlaç etkileşimleri)

  • Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (Doksapram etiketi, İlaç etkileşimleri)

  • Dorzolamid ve timololkarbonik anhidraz inhibitörüOrta

    If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Dorzolamid ve timolol etiketi, Uyarılar ve önlemler)

  • DulaglutidGLP-1 reseptör agonistiOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • DuloksetinSNRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Duloksetin etiketi, Uyarılar ve önlemler)

  • EfedrinsempatomimetikOrta

    • Pr e ssor Effect with Concomitant Oxytocic Drugs : Pressor effect of sympathomimetic pressor amines is potentiated (5.1) (Efedrin etiketi, Uyarılar ve önlemler)

  • EksenatidGLP-1 reseptör agonistiOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • EmpagliflozinSGLT2 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Empagliflozin ve metforminSGLT2 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Ergotamin ve kafeinergot alkaloidiOrta

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Esmololbeta blokerOrta

    Sympathomimetic drugs: Dose adjustment needed (7) (Esmolol etiketi, İlaç etkileşimleri)

  • EssitalopramSSRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (Essitalopram etiketi, Uyarılar ve önlemler)

  • EstazolambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Estazolam etiketi, Uyarılar)

  • FluoksetinSSRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. (Fluoksetin etiketi, Uyarılar ve önlemler)

  • FluvoksaminSSRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (Fluvoksamin etiketi, Uyarılar ve önlemler)

  • GlibenklamidsülfonilüreOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Glibenklamid ve metforminsülfonilüreOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • GlimepiridsülfonilüreOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • GlipizidsülfonilüreOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Glipizid ve metforminsülfonilüreOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Guanfasinalfa adrenerjik agonistOrta

    In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine. (Guanfasin etiketi, Uyarılar ve önlemler)

  • İnsülin aspartinsülinOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • İnsülin degludekinsülinOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • İnsülin detemirinsülinOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • İnsülin glarjininsülinOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • İnsülin lisproinsülinOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • KanagliflozinSGLT2 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Kandesartananjiyotensin II reseptör blokeri (ARB)Orta

    Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (Kandesartan etiketi, Uyarılar ve önlemler)

  • KetaminMSS depresanıOrta

    Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (Ketamin etiketi, Uyarılar ve önlemler)

  • KlobazambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Klobazam etiketi, Uyarılar ve önlemler)

  • Klomipramintrisiklik antidepresanOrta

    Close supervision and careful adjustment of dosage are required when clomipramine hydrochloride capsules are administered with anticholinergic or sympathomimetic drugs. (Klomipramin etiketi, İlaç etkileşimleri)

  • KlonazepambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Klonazepam etiketi, Uyarılar)

  • KlorazepatbenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Klorazepat etiketi, Uyarılar)

  • KlordiazepoksitbenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Klordiazepoksit etiketi, Uyarılar)

  • Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Klordiazepoksit ve klidinyum etiketi, Uyarılar)

  • The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Levomilnasipran etiketi, Uyarılar ve önlemler)

  • Levotiroksintiroid hormonuOrta

    Sympathomimetics Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. (Levotiroksin etiketi, İlaç etkileşimleri)

  • Lidokainlokal anestezikOrta

    Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (Lidokain etiketi, İlaç etkileşimleri)

  • LinagliptinDPP-4 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Linagliptin ve metforminDPP-4 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • LiraglutidGLP-1 reseptör agonistiOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • LisdeksamfetaminMSS uyarıcısıOrta

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • LorazepambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Lorazepam etiketi, Uyarılar ve önlemler)

  • MetforminbiguanidOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • MetildopaantihipertansifOrta

    If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Metildopa etiketi, İlaç etkileşimleri)

  • MetilfenidatMSS uyarıcısıOrta

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Metolazontiyazid diüretikOrta

    Sympathomimetics Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. (Metolazon etiketi, İlaç etkileşimleri)

  • MiglitolantidiyabetikOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • MilnasipranSNRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (Milnasipran etiketi, Uyarılar ve önlemler)

  • MirtazapinantidepresanOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (Mirtazapin etiketi, Uyarılar ve önlemler)

  • ModafinilMSS uyarıcısıOrta

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Naltrekson ve bupropionopioid antagonistiOrta

    …tumor or infection, or metabolic disorders (e.g., hypoglycemia, hyponatremia, severe hepatic impairment, and hypoxia) excessive use of alcohol or sedatives, addiction to cocaine or stimulants, or withdrawal from sedatives patients with diabetes treated with insulin and/or oral diabetic medications (sulfonylureas and meglitinides) that may cause hypoglycemia concomitant… (Naltrekson ve bupropion etiketi, Uyarılar ve önlemler)

  • NateglinidmeglitinidOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Nortriptilintrisiklik antidepresanOrta

    Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs. (Nortriptilin etiketi, İlaç etkileşimleri)

  • OksazepambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Oksazepam etiketi, Uyarılar)

  • Olanzapin ve fluoksetinantipsikotikOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Olanzapin ve fluoksetin etiketi, Uyarılar ve önlemler)

  • Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • ParoksetinSSRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Paroksetin etiketi, Uyarılar ve önlemler)

  • PioglitazontiyazolidindionOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Pioglitazon ve glimepiridtiyazolidindionOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Pioglitazon ve metformintiyazolidindionOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Propranololbeta blokerOrta

    Pharmacodynamic Drug-Drug Interactions Adrenergic Agonists: Beta-blockers may antagonize the antihypertensive effects of clonidine, and rebound hypertension may result if clonidine is withdrawn abruptly. (Propranolol etiketi, İlaç etkileşimleri)

  • Protriptilintrisiklik antidepresanOrta

    Drug Interactions When protriptyline is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required. (Protriptilin etiketi, İlaç etkileşimleri)

  • • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • RepaglinidmeglitinidOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • RitonavirantiretroviralOrta

    Anesthetic: meperidine ↓ meperidine/ ↑ normeperidine (metabolite) Dosage increase and long-term use of meperidine with ritonavir are not recommended due to the increased concentrations of the metabolite normeperidine which has both analgesic activity and CNS stimulant activity (e.g., seizures). (Ritonavir etiketi, İlaç etkileşimleri)

  • SaksagliptinDPP-4 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Saksagliptin ve metforminDPP-4 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • SemaglutidGLP-1 reseptör agonistiOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • SertralinSSRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Sertralin etiketi, Uyarılar ve önlemler)

  • SitagliptinDPP-4 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Sitagliptin ve metforminDPP-4 inhibitörüOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • SitalopramSSRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. (Sitalopram etiketi, Uyarılar ve önlemler)

  • SolriamfetolMSS uyarıcısıOrta

    Risk of Abuse and Dependence Phentermine is related chemically and pharmacologically to amphetamine (d- and d l l-amphetamine) and other related stimulant drugs that have been extensively abused. (Fentermin etiketi, Uyarılar ve önlemler)

  • Sotalolbeta blokerOrta

    Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (Sotalol etiketi, İlaç etkileşimleri)

  • The most commonly described clinical features in reports of anaphylaxis were dermatologic symptoms (including urticaria, rash, erythema, flushing and skin eruption); and clinically important hypotension often requiring the use of vasopressors for circulatory support. (Sugammadeks etiketi, Uyarılar ve önlemler)

  • Circulatory Shock Circulatory shock with fever, severe hypotension, and confusion requiring intravenous fluid resuscitation and vasopressors has occurred within minutes to hours of re-challenge with trimethoprim-sulfamethoxazole products in patients with history of recent (days to weeks) exposure to sulfamethoxazole and trimethoprim. (Sülfametoksazol ve trimetoprim etiketi, Uyarılar)

  • TemazepambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Temazepam etiketi, Uyarılar)

  • Timololbeta blokerOrta

    If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Timolol etiketi, Uyarılar ve önlemler)

  • TiotropiumantikolinerjikOrta

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Tiotropium etiketi, İlaç etkileşimleri)

  • TirzepatidGLP-1 reseptör agonistiOrta

    • A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (Fentermin etiketi, Uyarılar ve önlemler)

  • Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (Tolkapon etiketi, İlaç etkileşimleri)

  • TriazolambenzodiazepinOrta

    Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Triazolam etiketi, Uyarılar ve önlemler)

  • VenlafaksinSNRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, busipirone, amphetamines, and St. (Venlafaksin etiketi, Uyarılar ve önlemler)

  • VilazodonSSRIOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, meperidine, methadone, lithium, tramadol, tryptophan, buspirone, amphetamines, and St. (Vilazodon etiketi, Uyarılar ve önlemler)

  • VortioksetinantidepresanOrta

    The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, meperidine, methadone, buspirone, amphetamines, and St. (Vortioksetin etiketi, Uyarılar ve önlemler)

  • ZiprasidonantipsikotikOrta

    The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (Ziprasidon etiketi, Uyarılar ve önlemler)

Minör değinmeler (38)

  • AlmotriptantriptanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • AmantadinantikolinerjikMinör

    Drug Interactions Careful observation is required when amantadine hydrochloride is administered concurrently with central nervous system stimulants. (Amantadin etiketi, İlaç etkileşimleri)

  • Amoksapintrisiklik antidepresanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Asebutololbeta blokerMinör

    A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (Asebutolol etiketi, Uyarılar)

  • Severe reactions have required intervention with vasopressor agents and supportive measures. (Benzonatat etiketi, Uyarılar)

  • Bromokriptindopamin agonistiMinör

    There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (Bromokriptin etiketi, İlaç etkileşimleri)

  • Buspironserotonerjik ilaçMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Dekstrometorfanserotonerjik ilaçMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Dekstrometorfan ve kinidinserotonerjik ilaçMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Dihidroergotaminergot alkaloidiMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Doksepintrisiklik antidepresanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • EletriptantriptanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • FlibanserinMSS depresanıMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • FrovatriptantriptanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • GranisetronQT aralığını uzatan ilaçMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • İpratropiumantikolinerjikMinör

    ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (İpratropium etiketi, İlaç etkileşimleri)

  • Labetalolbeta blokerMinör

    Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods. (Labetalol etiketi, İlaç etkileşimleri)

  • Lityumserotonerjik ilaçMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • NaratriptantriptanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • NefazodonantidepresanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • OndansetronQT aralığını uzatan ilaçMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Palonosetronserotonerjik ilaçMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • PerfenazinantipsikotikMinör

    If a vasopressor is needed, norepinephrine may be used. (Perfenazin etiketi, Uyarılar)

  • PetidinopioidMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • PropofolMSS depresanıMinör

    These effects are responsive to discontinuation of DIPRIVAN, intravenous fluid administration, and/or vasopressor therapy. (Propofol etiketi, Uyarılar ve önlemler)

  • Prukalopridserotonerjik ilaçMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Ramelteonsedatif-hipnotikMinör

    In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (Ramelteon etiketi, Uyarılar ve önlemler)

  • RizatriptantriptanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Siklobenzaprinkas gevşeticiMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • SumatriptantriptanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • TapentadolopioidMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • TiagabinantikonvülsanMinör

    In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (Tiagabin etiketi, Uyarılar)

  • TramadolopioidMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • TrazodonantidepresanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • Trimipramintrisiklik antidepresanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

  • ZolmitriptantriptanMinör

    The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (Fentermin etiketi, Uyarılar ve önlemler)

Kullandığınız her şeyi Fentermin ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.